Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retro...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoir: Kazuhito Suzuki (22688384) (author)
Rannpháirtithe: Miku Ito (22688387) (author), Chika Sakai (5712761) (author), Hiroaki Tsuchiya (2437369) (author), David Bin-Chia Wu (7251623) (author), Yosuke Koroki (12979839) (author)
Foilsithe / Cruthaithe: 2025
Ábhair:
Medicine
Pharmacology
Biotechnology
Immunology
Cancer
Science Policy
Mental Health
Daratumumab
duration of treatment
lenalidomide
newly diagnosed multiple myeloma
overall survival
real-world evidence
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla